Comparative Treatment Approaches for Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) represents the predominant primary malignancy of the liver, often arising in the context of chronic liver disease and cirrhosis. Curative options for early‐stage HCC include surgical resection and a range of ablative modalities, whereas intermediate and advanced stages may be addressed by locoregional therapies such as transcatheter arterial chemoembolisation (TACE) or systemic agents. Surgical resection remains the gold standard for patients with preserved hepatic reserve and resectable disease, offering superior long‐term survival but at the cost of higher perioperative risk and longer hospitalisation. Minimally invasive ablative techniques, notably radiofrequency ablation (RFA) and microwave ablation (MWA), provide effective tumour control for small lesions, lower complication rates and shorter recovery times, yet may be associated with higher rates of local recurrence. The advent of stereotactic ablative radiotherapy and irreversible electroporation has further expanded the therapeutic armamentarium for patients unsuitable for surgery or thermal ablation. Comparative analyses focus on metrics such as overall survival, disease-free survival and treatment-related morbidity, with patient selection guided by tumour size, number, location, liver function and comorbidities. Recent global studies have emphasised the role of propensity-score matching and network meta-analysis to mitigate selection bias and to refine evidence-based guidelines for optimal allocation of resection versus ablation strategies.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Comparative Treatment Approaches for Hepatocellular Carcinoma publication trend

The graph below shows the total number of articles in comparative treatment approaches for hepatocellular carcinoma across all publications each year (not limited to Nature Index journals).

Technical terms

Radiofrequency ablation (RFA): A percutaneous technique that uses high-frequency alternating current to generate heat and induce tumour necrosis.

Microwave ablation (MWA): A thermal ablation method employing electromagnetic microwaves to produce rapid and larger coagulation zones in tumour tissue.

Transcatheter arterial chemoembolisation (TACE): A locoregional therapy combining intra-arterial chemotherapy with embolic particles to induce ischaemia and cytotoxicity in HCC lesions.

Propensity-score matching (PSM): A statistical method that balances baseline characteristics between treatment groups in observational studies to reduce bias.

Overall survival (OS): The duration from treatment initiation until death from any cause, used to assess treatment efficacy.

Disease-free survival (DFS): The interval from curative treatment to tumour recurrence or death, reflecting the durability of tumour control.

References

1. Improved Survival Outcomes with Surgical Resection Compared to Ablative Therapy in Early-Stage HCC: A Large, Real-World, Propensity-Matched, Multi-Centre, Australian Cohort Study. Cancers (2023).
2. Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis. Health Technology Assessment (2023).
3. Thermal ablation versus liver resection for hepatocellular carcinoma in patients with cirrhosis: a systematic review and meta-analysis of propensity-score matched studies. Clinical and Experimental Medicine (2024).